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Abstract
Background: Protein kinase C δ (PKCδ) is known to be an important regulator of apoptosis, having mainly pro- but
also anti-apoptotic effects depending on context. In a previous study, we found that PKCδ interacts with the
pro-apoptotic protein Smac. Smac facilitates apoptosis by suppressing inhibitor of apoptosis proteins (IAPs).
We previously established that the PKCδ-Smac complex dissociates during induction of apoptosis indicating a
functional importance. Because the knowledge on the molecular determinants of the interaction is limited, we
aimed at characterizing the interactions between PKCδ and Smac.
Results: We found that PKCδ binds directly to Smac through its regulatory domain. The interaction is enhanced
by the PKC activator TPA and seems to be independent of PKCδ catalytic activity since the PKC kinase inhibitor
GF109203X did not inhibit the interaction. In addition, we found that C1 and C2 domains from several PKC isoforms
have Smac-binding capacity.
Conclusions: Our data demonstrate that the Smac-PKCδ interaction is direct and that it is facilitated by an open
conformation of PKCδ. The binding is mediated via the PKCδ regulatory domain and both the C1 and C2 domains
have Smac-binding capacity. With this study we thereby provide molecular information on an interaction between
two apoptosis-regulating proteins.
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Background
Apoptosis is a form of programmed cell death that was
first described as a process of cellular turnover import-
ant for tissue homeostasis under physiologic conditions
[1]. It also acts as a barrier to cancer development and
dysregulation of apoptosis is a hallmark of most, if not
all, cancer types [2]. Regulation of apoptosis is complex
and involves multiple signaling pathways and proteins
that are commonly grouped into two processes, the
extrinsic apoptotic pathway that is activated by ligand-
receptor interactions at the cell surface and the intrinsic
apoptotic pathway that is activated by permeabilization
of the mitochondrial membrane. Both pathways lead to
activation of caspases, a group of proteins that are effec-
tors of apoptosis [3].
When mitochondria are permeabilized during intrinsic
apoptosis, proteins that participate in stimulation of apop-
tosis are released from the mitochondrial intermembrane
space. One of the proteins released is Smac. Smac is a
25 kDa protein requiring posttranslational modification
for maturation and activation. After translation, a
mitochondrial targeting signal (MTS) located in the
N-terminal part of the protein directs it to mitochondria
and upon entry, the MTS is cleaved off yielding mature
Smac [4]. When released from mitochondria, mature
Smac facilitates apoptosis by binding to and inhibiting
proteins of the inhibitor of apoptosis protein (IAP) family
such as X-linked inhibitor of apoptosis protein (XIAP)
and cellular inhibitor of apoptosis protein (cIAP) 1/2,
which leads to disinhibition of caspases [4–6] and redirec-
tion of TNFα-signaling towards caspase-8 activation [7, 8].
Besides protein localization, Smac has been reported to be
a target of several kinases that act to regulate its apoptotic
functions [9–11]. Furthermore, Smac may have additional
apoptotic functions that are independent of its ability to
bind IAPs [12].
The apoptotic pathways are influenced by numerous
signaling proteins and among them is the protein kinase
C (PKC) family of proteins. Several PKC isoforms have
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been linked to regulation of apoptosis. One of these iso-
forms is PKCδ, a protein known to be an important
regulator of apoptosis with mainly pro-apoptotic func-
tions [13, 14]. However, PKCδ has several anti-apoptotic
functions as well which has been described in a previous
study in our group as well as in several other publica-
tions [15–18].
In a previous study we found that PKCδ and Smac
interact in breast cancer cell lines and that the inter-
action is disrupted during paclitaxel-mediated cell
death [19]. Since the interaction between the two pro-
teins appears to have a role in cell death, we aimed
at characterizing the molecular determinants of the
interaction. In this study, we show that PKCδ and
Smac bind directly to each other via the regulatory
domain of PKCδ. We also show that the binding be-
tween the proteins is stimulated when PKCδ is in an
open conformation.
Results
PKCδ and Smac bind directly to each other and the
binding is stimulated when PKCδ is in an open
conformation
In order to analyze the effect of PKC activation and in-
hibition on the interaction with Smac, COS-7 cells were
transfected with tagged PKCδ- and Smac-constructs
followed by co-immunoprecipitation. We observed that
PKCδ primarily interacts with a larger Smac variant,
conceivably corresponding to Smac with an intact MTS
(Fig. 1a and b), and this interaction was further en-
hanced by treatment with the PKC activator TPA (Fig. 1b
and c). However, treatment with the PKC inhibitor
GF109203X influenced neither the basal nor the TPA-
facilitated PKCδ-Smac interaction (Fig. 1c).
A similar effect of TPA was observed by immunopre-
cipitation of endogenous PKCδ from MCF-7 breast can-
cer cells expressing a HSV-tagged Smac (Fig. 1d). While
Fig. 1 PKC activation enhances the interaction between PKCδ and Smac in cells. a Schematic of Smac structure. b, c COS-7 cells were transfected
with vectors encoding EGFP-tagged full-length PKCδ and Smac-FLAG. After transfection, indicated cells were treated with 16 nM TPA (b) with or
without 2 μM GF109203X (c) for 16 h. Lysates were then used for GFP-immunoprecipitation. d MCF-7 cells were transfected with a vector encoding
Smac-HSV. After transfection, indicated cells were treated with 16 nM TPA for 16 h. Lysates were then used for PKCδ-immunoprecipitation. Figures are
representatives from three experiments. Asterisk indicates non-specific band
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overexpressed PKCδ in COS-7 cells preferentially co-
precipitated immature Smac harboring an intact MTS,
endogenous PKCδ preferentially co-precipitated mature
Smac in MCF-7 cells. In this setting, TPA treatment en-
abled interaction with the immature, MTS-containing
form (Fig. 1d).
To investigate if PKCδ and Smac bind directly to each
other, purified recombinant His-tagged Smac and GST-
tagged PKCδ were incubated in a binding reaction
followed by GST-immunoprecipitation. We found that
His-Smac was co-precipitated with GST-PKCδ whereas
almost no co-precipitation was seen with GST alone,
showing that the proteins can directly bind each other
(Fig. 2a). To investigate if the activation status of PKCδ
affects its interaction with Smac also in this setting, TPA
and/or GF109203X were added to the binding reaction.
Both TPA and GF109203X, alone and in combination,
seemed to yield an increased binding. However, upon
quantification only the combination gave a significant
increase (Fig. 2b and c). Since GF109203X inhibits PKC
activity but also stabilizes the open, active conformation
of PKCs [20], the results indicate that the Smac-PKCδ
interaction is facilitated when PKCδ is in an open con-
formation, independent of PKCδ activity.
Smac binds to the regulatory domain of PKCδ
We have previously reported that interaction with PKCδ
is dependent on the IAP-binding domain of Smac [19].
Therefore, we focused on identifying the specific do-
mains of PKCδ necessary for mediating the interaction.
The PKCδ protein consists of multiple domains that can
be grouped into an N-terminal regulatory domain and a
C-terminal catalytic domain (Fig. 3a). To narrow down
which parts of PKCδ that mediate the binding to Smac,
co-immunoprecipitation was performed on COS-7 cells
transfected with FLAG-tagged full-length Smac together
with GFP-tagged full-length PKCδ or the isolated regula-
tory or catalytic domains. Smac co-precipitated with
full-length PKCδ and the regulatory domain but not
with the catalytic domain of PKCδ (Fig. 3b). We pro-
ceeded with analyzing which parts of the regulatory
domain that could co-precipitate Smac in our assay.
Fig. 2 PKCδ and Smac bind directly to each other. a–c His-Smac was incubated with GST-PKCδ or GST for 1 h before GST-immunoprecipitation.
In b, His-Smac was incubated with GST-PKCδ for all samples. Fractions were collected and analyzed with Western blot. 20 nM TPA and/or 2 μM
GF109203X (GFX) were included in the binding reactions where indicated. Figures are representatives from three experiments. Asterisk indicates
non-specific band. c Quantification of signal intensity of Smac bands in the IP-fractions from (b). Band intensities were normalized to input
fractions and control. Data represents mean ± SEM from three independent experiments. * indicates p < 0.05
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Constructs containing either the C1 or the C2 domains
had the highest capacity to co-precipitate Smac (Fig. 3c).
However, isolated C1 or pseudosubstrate domains did
not interact with Smac to a large extent. Altogether, the
results indicate that there is more than one site in the
regulatory domain of PKCδ that have the ability to
bind Smac.
Smac can interact with several PKC-isoforms
Since PKC isoforms have a large degree of homology
among its family members [21], we wanted to examine if
other PKC family members have the ability to interact
with Smac. To investigate this, COS-7 cells were trans-
fected with vectors encoding tagged, full length versions
of different PKC family members and Smac which was
followed by co-immunoprecipitation. The extent to
which Smac was co-precipitated varied between PKC
family members. However, all PKC family members in-
cluded were capable of co-precipitating Smac to some
extent (Fig. 4a). We next analyzed if the tandem C1aC1b
domain or the C2 domain from these isoforms was
sufficient for interaction with Smac. All tested constructs
could co-precipitate Smac but in general, the strongest as-
sociations were seen with the tandem C1aC1b constructs
(Fig. 4b). This indicates that Smac has the ability to inter-
act with several PKC isoforms besides PKCδ.
Amongst the PKC family members, PKCδ is known to
be the most extensively tyrosine-phosphorylated isoform
[22]. The importance of tyrosine phosphorylation in
regulation of PKCδ functions has been shown in several
publications [16, 22, 23]. Because of this, we investigated
if phosphorylation on some key tyrosine residues on
PKCδ could alter the association with Smac. To pursue
this, vectors encoding phosphomimetic mutants of
PKCδ were generated, having a tyrosine residue mutated
to aspartate to mimic the negative charge imparted by
phosphorylation. The vectors generated encoded Y64D,
Y155D or Y313D point mutations and these residues were
tested because they have been shown to induce changes in
substrate binding upon phosphorylation [23–25]. The vec-
tors were transfected into COS-7 cells together with
tagged, full-length Smac. None of the phosphomimetic
PKCδ mutants generated showed any change in Smac-
binding compared to wild-type PKCδ under neither basal
nor TPA-stimulated conditions (Fig. 4c). The results
suggest that constitutive mono-phosphorylation on any of
the tyrosine residues tested does not influence the binding
between PKCδ and Smac.
Fig. 3 Smac binds to the regulatory domain of PKCδ. a Schematic of PKCδ structure. b, c COS-7 cells were transfected with vectors encoding full-length
Smac-FLAG together with vectors encoding EGFP-fusions of full-length PKCδ, the regulatory domain or the catalytical domain (b) or different
combinations of regulatory domain subregions (c). Lysates were then used for GFP-immunoprecipitation. FL = Full-length, RD = Regulatory domain,
CD = Catalytical domain, PS = Pseudosubstrate domain. Figures are representatives from three experiments. Asterisk indicates non-specific band
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Discussion
In this study, we have characterized the interaction be-
tween PKCδ and Smac and found that the two proteins
bind directly to each other. Furthermore, the results
indicate that the interaction is facilitated by an open
conformation of PKCδ.
Our data showed that TPA, a PKC activator, stimulates
the interaction in both MCF-7 and COS-7 cells. The
PKC inhibitor GF109203X did not suppress the inter-
action and it potentiated the effect of TPA on recombin-
ant proteins. GF109203X is an inhibitor described to
inhibit PKC activity by stabilizing an active, open con-
formation [20]. When TPA binds to the C1 domain, a
hydrophobic surface is formed over the C1 domain [26],
which is a key step in promoting an open PKC conform-
ation. Therefore, our results point to a model in which the
interaction between PKCδ and Smac is independent of
kinase activity but is facilitated by an open conformation.
The significance of the Smac-PKCδ interaction re-
mains to be fully understood. Since the interaction takes
place via the regulatory domain of PKCδ, it is less likely
that it directly blocks the catalytic site of PKCδ. A clue
to the function of the interaction can perhaps instead be
gained from the observation that it is the tandem
C1aC1b domain and the C2 domain of PKCδ that seem
to co-precipitate Smac the most. These domains regulate
PKC activity in part by binding co-factors required for
activation. C1 domains bind diacylglycerol whereas C2
domains bind calcium ions, both of which serve as acti-
vators of PKC function [13]. However, PKCδ lacks a
classical C2 domain and instead has a C2-like domain
that does not bind calcium ions, rendering the protein
calcium-independent [22]. Since Smac interacts the most
with these domains, it is possible that the interaction has
a regulatory effect on PKCδ activity. Because our results
point to a model in which an open PKCδ conformation
facilitates the interaction, it can be speculated that the
interaction could modulate the activity of enzymatically
active PKCδ, either by stabilizing the open conformation
or by inhibiting its catalytic function through allosteric
regulation.
Through our studies, we found that all PKC family
members that were tested had the ability to co-precipitate
Smac and that both the tandem C1aC1b- and the C2-
Fig. 4 Smac can interact with several PKC-isoforms. a, b, c COS-7
cells were transfected with vectors encoding full-length Smac-FLAG
and EGFP-fusions of full-length PKC isoforms (a), C1/C2 domains from
different isoforms (b) or mutated full-length PKCδ variants carrying a
tyrosine-to-aspartate mutation on Tyr-64 (Y64D), Tyr-155 (Y155D) or
Tyr-313 (Y313D) (c). After transfection, indicated cells were treated with
16 nM TPA. Lysates were then used for GFP-immunoprecipitation.
Figures are representatives from three experiments. Asterisk indicates
non-specific band
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domains of different isoforms contain structures that can
interact with Smac. In contrast to this, no interaction with
Smac was found when endogenous PKCα or PKCε was
precipitated in the MDA-MB-231 breast cancer cell line
[19]. This suggests that although PKCδ is the only PKC
family member described to interact with Smac so far,
other PKCs seem to have the ability to interact with Smac
but may not do so under endogenous conditions. One po-
tential explanation for this is that the levels of the respect-
ive PKC family members are higher upon overexpression
than in the endogenous settings tested in the previous
study. This may result in the appearance of less spe-
cific interactions. Localization of proteins could also
potentially explain why an interaction is only seen
with PKCδ under endogenous conditions. Smac is located
in mitochondria under non-stimulated conditions and in
previous studies, it has been reported that PKCδ can
translocate to mitochondria and interact with mitochon-
drial proteins [4, 15, 27, 28]. Previously, we have shown
that the Smac-PKCδ interaction takes place in a
mitochondria-rich fraction and not in the cytosol [19]. If
the other PKC isoforms are present in lower amounts in
mitochondria compared to PKCδ, this could potentially
explain this preference of interaction under endogenous
conditions. However, it cannot be excluded that Smac
may interact with other PKC isoforms in other cell types.
We noted that PKCδ could co-precipitate both mature
Smac as well as the immature pro-form carrying a mito-
chondrial targeting signal. In COS-7 cells, PKCδ prefer-
entially co-precipitated the immature form whereas the
opposite was observed in MCF-7 cells under non-
stimulated conditions. This could potentially be ex-
plained by our approach in which we performed the
co-immunoprecipitation with endogenous PKCδ in
MCF-7 cells whereas in COS-7 cells, both proteins where
exogenously expressed through plasmid transfections. It
could be that overexpression of PKCδ in COS-7 cells
causes the protein to accumulate in the cytoplasm,
stimulating interaction with Smac prior to mitochondrial
import and maturation.
Our studies on phosphomimetic mutants showed that
substitution of tyrosine to aspartate, a negatively charged
amino acid, did not change the binding affinity of PKCδ
to Smac. Aspartate mimics the charge but not fully the
structure of phosphotyrosine and does therefore not com-
pletely replicate a phosphorylated residue. Phosphoryla-
tions on the sites tested have previously been reported to
modify the function and/or activity of PKCδ [23–25].
Since tyrosine phosphorylation is more extensive on PKCδ
than on other PKC family members, we hypothesized that
phosphorylation could be an explanation as to why we
have been unable to detect endogenous Smac interaction
with other PKC family members. The lack of visible differ-
ences on the PKCδ-Smac interaction in our studies on the
phosphomimetic mutants do not support a hypothesis
that the interaction is influenced by phosphorylation on
the residues tested in our study.
Conclusions
Our data demonstrate that the two apoptosis-regulating
proteins Smac and PKCδ bind directly to each other.
The interaction is mediated via the regulatory domain of
PKCδ and the C1 and C2 domains of several PKC
isoforms have Smac-binding capacity. The binding is
facilitated by exposure of the regulatory domain of PKCδ
and thus on an open conformation of the protein.
Methods
Plasmids
The plasmid vectors encoding Smac-HSV and Smac-
FLAG have previously been described [4, 29]. Vectors
encoding full-length EGFP-tagged PKCα, βI, βII, δ, ε, η
and θ as well as isolated PKC domains have been
described previously [30–33]. Vectors encoding phospho-
mimetic mutants of PKCδ were generated from the full-
length EGFP-tagged PKCδ plasmid using site-directed
mutagenesis. A pEGFP-N1 vector was used as GFP-
control in experiments. The tags used are expected to not
affect protein function [34, 35].
Cell culture
MCF-7 cells were grown in RPMI 1640 and COS-7 cells
were grown in DMEM/High Glucose (Thermo Scientific).
All media were supplemented with 10 % fetal bovine
serum (Biosera), 100 IU/ml penicillin (Thermo Scientific)
and 100 μg/ml streptomycin (Thermo Scientific). RPMI
medium was additionally supplemented with 1 mM so-
dium pyruvate (PAA Laboratories). Cells were grown
in 10 cm Petri dishes (Falcon) at 37 °C and 5 %
CO2. When indicated, cells were treated with 16 nM
12-O-tetradecanoylphorbol-13-acetate (Sigma) or 2 μM
GF109203X.
Immunoprecipitation
For immunoprecipitation procedures, 2 x 106 cells were
seeded in 10 cm Petri dishes. Transfections were per-
formed as described previously [36]. Transfection con-
trols were incubated with growth medium without
serum or penicillin-streptomycin. For TPA-stimulation,
16 nM TPA was added to the cells after transfection and
16 h after transfection, cells were collected and lysed.
Immunoprecipitations were performed using MACS
Separation Columns together with μMACS GST Isolation
Kit for GST-tagged proteins and μMACS GFP-Tagged
Protein Isolation Kit for GFP-tagged proteins (Miltenyi
Biotec). For PKCδ-immunoprecipitations, 1 μg anti-PKCδ
antibody (Santa Cruz) was used together with Multi-
MACS protein G kit and μMACS Protein G Microbeads
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(Miltenyi Biotec) with 1 μg normal rabbit IgG-antibody
(Santa Cruz) as control. All immunoprecipitations were
performed as described in manufacturer’s protocol with
the exception of GST-immunoprecipitations where bind-
ing reactions were incubated with beads for 90 min. For
all Western blots performed with samples from immuno-
precipitation, 2 % of each sample was loaded for input
fractions and 48 % was loaded for IP fractions.
In vitro interaction of recombinant, purified PKCδ and
Smac
The in vitro interaction was studied by incubating puri-
fied, His-tagged Smac protein (0.5 μg) with GST-tagged
PKCδ (0.5 μg, Enzo Life Sciences) in GST-pulldown buf-
fer containing 20 mM Tris-HCl pH 7.5, 0.1 mM EDTA,
100 mM NaCl, 1 mM DTT and 40 μl/ml Complete
Protease Inhibitors (Roche). The purified His-Smac had
previously been produced in E. coli using a pET-28a
expression vector. For controls, GST-tagged PKCδ was
substituted for purified GST. Immunoprecipitation was
thereafter performed as described in the material and
methods section.
Western blot
Western blot was performed as described in a previous
publication [37]. Primary antibodies used were anti-
PKCδ (1:500, Santa Cruz), anti-Smac (1:500, Santa Cruz),
anti-Actin (1:2000, MP Biomedicals), anti-HSV (1:1000,
Novagen), anti-GST (1:2000, GE Healthcare) and anti-GFP
(1:1000, Invitrogen). Secondary horseradish peroxidase-
labeled antibodies used were from GE Healthcare and
Dako. For the chemiluminescent reaction, Supersignal
Substrate (Thermo Scientific) was used according to man-
ufacturer’s instructions. Chemiluminescence was detected
with a LAS-1000 charge-coupled device camera (Fujifilm)
and Image Reader LAS-1000 Pro v2.6 software (Fujifilm).
Image quantifications were performed using ImageJ 1.48v
and by normalizing band intensities to input fractions
and control.
Site-directed mutagenesis
Site-directed mutagenesis was performed using QuikChange
II Site-Directed Mutagenesis Kit (Agilent) according to
manufacturer’s protocol. 20 μg of FL-PKCδ-EGFP plasmid
was used for each PCR-reaction. Primer sequences used
for the PCR-reaction were the following: Y64D mutation
forward primer – TTCGATGCCCACATCGATGAGG
GGCGCGTCATC, Y64D mutation reverse primer –
GATGACGCGCCCCTCATCGATGTGGGCATCGAA,
Y155D mutation forward primer – CAGGCCAAAATC
CACGACATCAAGAACCATGAG, Y155D mutation re-
verse primer – CTCATGGTTCTTGATGTCGTGGAT
TTTGGCCTG, Y313D mutation forward primer – GAG
CCTGTTGGGATAGATCAGGGTTTCGAGAAG, Y313D
mutation reverse primer – CTTCTCGAAACCCTGATC
TATCCCAACAGGCTC. All primers were ordered from
Invitrogen. Bacteria were grown for 24 h before Miniprep
was performed using the JETquick Plasmid Miniprep Spin
Kit (Genomed) according to manufacturer’s protocol. The
resulting minipreps were checked for successful mutation
by sequencing of the plasmids. The minipreps which
had incorporated the mutation were then amplified by
transformation of XL-2 Blue Ultracompetent cells
(Agilent) followed by Maxiprep using the JETstar
Plasmid Purification MAXI kit (Genomed) according to
manufacturer’s instructions.
Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics 22. Significance of difference was tested using
analysis of variance (ANOVA) followed by Tukey’s HSD
test. Differences were considered significant if the p-value
was below 0.05.
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